HCA · Q3 2025 Earnings

Cautious

HCA Healthcare

Reported October 24, 2025

30-second summary

HCA beat its way to a full-band FY2025 raise — revenue, EPS, net income, and EBITDA all up — driven by 6.6% revenue per equivalent admission and a $240M Q3 supplemental payments tailwind concentrated in Tennessee, Texas, and Kansas. But management quietly withdrew the 2–3% equivalent admissions growth target it had just reset last quarter, declined to give 2026 guidance citing federal policy uncertainty, and explicitly reframed supplemental payments as "complex, variable in timing." The print is operationally strong; the forward narrative is the most defensive HCA has sounded in years.

Headline numbers

EPS

Q3 FY2025

$6.96

Revenue

Q3 FY2025

$19.16B

+9.6% YoY

Operating margin

Q3 FY2025

12.6%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$19.16B	+9.6%	$18.61B	+3.0%
EPS	$6.96	—	$6.84	+1.8%
Operating margin	12.6%	—	13.0%	-40bps

Guidance

HCA raised FY2025 revenue, EPS, net income, and Adjusted EBITDA guidance across the board, driven by Q3 operational outperformance and strong pricing execution.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY2025	$74.0 billion to $76.0 billion	$75.0 billion to $76.5 billion	low end +$1.0B; midpoint +$0.75B; high end +$0.5B	Raised
Diluted EPS	FY2025	$25.50 to $27.00	$27.00 to $28.00	low end +$1.50; high end +$1.00; midpoint +$1.25	Raised
Net Income Attributable to HCA Healthcare, Inc.	FY2025	$6.11 billion to $6.48 billion	$6.50 billion to $6.72 billion	low end +$0.39B; high end +$0.24B; midpoint +$0.32B	Raised
Adjusted EBITDA	FY2025	$14.70 billion to $15.30 billion	$15.25 billion to $15.65 billion	low end +$0.55B; high end +$0.35B; midpoint +$0.45B	Raised
Equivalent Admissions Growth	FY2025	2% to 3%	Withdrawn — no replacement	—	Withdrawn
Supplemental Payments Net Benefit YoY	FY2025	Flat to $100 million favorable	Withdrawn — no replacement	—	Withdrawn

Reaffirmed unchanged this quarter: Capital Expenditures (Approximately $5.0 billion)

Other KPIs

Q3 FY2025

Segment	Q3 FY2025
Adjusted EBITDA	$3.870 billion
Adjusted EBITDA Margin	20.2%
Operating Cash Flow	$4.416 billion
Same Facility Admissions Growth	2.1%
Occupancy Rate	71.7%
Average Length of Stay	4.660 days
Revenue per Equivalent Admission	$18,446
Inpatient Revenue per Admission	$19,908

Management tone

Q4-2024 anchor: confident volume momentum → Q1-2025: policy risk emerges → Q2-2025: volume guide cut, resiliency deferred → Q3-2025: earnings raised, but 2026 explicitly deferred and volume guide quietly withdrawn.

From "we'll quantify resiliency on Q4" to "we'll limit our early thoughts for 2026." Last quarter management committed to disclosing the resiliency program scale on the Q4 call. This quarter management walked that commitment back to "views on demand and the cost environment," saying: "Because of the fluid nature of the federal policy environment, we will limit our early thoughts for 2026... it is important to note that we are still early in next year's planning process and these preliminary views may change before our fourth quarter's earnings call when we will provide you with our guidance for 2026." A company that raises EPS guidance by $1.25 at the midpoint and then declines to frame the following year is signalling that the forward setup is genuinely unclear, not that the current quarter was weak.

Supplemental payments reframed from tailwind to variable revenue. A year ago supplemental payments were treated as a structural Medicaid offset. This quarter management explicitly said: "Regarding Medicaid supplemental payment programs, as we've said in the past, these programs are complex, variable in timing, and do not fully cover our costs to treat Medicaid patients." Combined with withdrawing the formal supplemental payments guide line and disclosing the $250–350M FY2025 net benefit only in Q&A, this is a deliberate distancing from a number that materially helped the print. The signal: don't model this as recurring run-rate.

From quantified volume guidance to qualitative long-term framing. Last quarter HCA reset equivalent admissions growth to 2–3% from 3–4%. This quarter the numeric guide is withdrawn entirely, replaced with "we continue to see solid demand across our markets for health care services and believe volumes will be within our long-term 2 to 3 percent growth range." Same number, removed accountability. With the respiratory season starting slow (50–70bps drag) and self-pay volumes down 6%, the qualitative reframing buys cover for a soft Q4 print on a metric that was previously a hard number.

EPTC: from "manageable" to "we still do not know how this policy will play out." On the enhanced premium tax credits set to affect 24M Americans, Hazen offered: "Today, we believe there is greater recognition by legislators of the negative impact this issue will have on families, small businesses, and individuals than earlier in the year. At this point, however, we still do not know how this policy will play out." This is more conditional than Q2's "manageable" framing — the legislative recognition is a positive incremental data point, but the explicit acknowledgment of unknowns alongside it signals management is no longer willing to underwrite a range of outcomes.

Recurring themes management leaned on this quarter:

Enhanced premium tax credits uncertainty as near-term policy riskMedicaid supplemental payment programs volatile and timing-dependentOperational resilience and margin expansion despite external headwindsVolume growth constrained by slow respiratory seasonStrong payer mix (commercial +3.7%) offsetting Medicaid/self-pay softness2026 guidance deferral due to federal policy fluidity

Risks management surfaced:

Enhanced premium tax credits program expiration affecting 24 million AmericansMedicaid supplemental payment programs do not fully cover costs and are variable in timingSlow start to respiratory season impacting admissions/ER visits by 50-70 basis pointsSelf-pay ER visits declined year-over-yearOperating cost pressures in certain areas (though expected to be offset by resiliency plan)

Q&A highlights

AJ Rice · Credit Suisse

Asked about potential step-up in elective procedure volumes in Q4 due to coverage concerns, and whether HCA can re-sign patients through emergency room if special enrollment periods are extended.

Management stated they are not sizing potential exchange impacts due to fluid situation, will provide more details on Q4 call once government extension terms are clarified. Confirmed financial counseling teams can connect patients to resources but cannot sign them up onsite.

Cannot quantify exchange volume impact until Q4 earnings callAwaiting clarity on government extension form and timingParalon and revenue cycle teams enhanced to help patients navigate Medicaid and exchange coverage

Justin Lake · Wolf Research

Asked for quantification of DTP benefit for 2025 and normalized run rate going into 2026 before additional approvals.

Management indicated 2025 DTP benefit will be approximately $2.3-2.4 billion, with updated guidance of $250-350 million net benefit from state supplemental payments for full year 2025 vs 2024. Confirmed guidance does not include additional pending state approvals.

2025 DTP benefit estimated at $2.3-2.4 billionState supplemental payments: $250-350 million favorable for full year 2025 vs 2024Q4 2025 expected to see $250 million net benefit from supplemental paymentsGuidance excludes any approved programs that may come after government reopens

Peter Chickering · Deutsche Bank

Questioned why guidance didn't increase significantly despite Q3 beat, and asked for bridge from Q3 to Q4 considering hurricane and supplemental payment impacts.

Management explained Q4 implied growth rate is high single-digits (~7%) after accounting for hurricane impact and supplemental payment decline; sequential growth Q3-Q4 in line with historical trends; guidance range allows for upside performance.

Q4 2025 implied growth rate approximately 7%Sequential Q3-Q4 growth in line with historical trendsGuidance range designed to accommodate range of outcomes including upside

Ben Hendrix · RBC Capital Markets

Asked for specific recognition amounts of supplemental state programs in Q3 and guidance, specifically for Tennessee and Texas.

Tennessee was largest Q3 driver with cash received; Texas application approved late in quarter (one month impact Q3); Kansas also approved (nine months recorded in Q3). Emphasized programs are complex with numerous pluses and minuses across portfolio.

Tennessee largest net benefit driver in Q3 2025Texas grandfathered application approved late Q3 with one month impactKansas approved with nine months of impact recorded in Q3 2025Aggregate $240 million net benefits from all state programs with multiple offsets

Scott Seidel · Goldman Sachs

Requested breakdown of Medicare volumes between Medicare Advantage and fee-for-service with case mix and acuity observations.

Medicare Advantage up 4.8% YoY; traditional Medicare case mix index up modestly; Medicare Advantage case mix flat to prior year. Overall Medicare combined up 3.4% adjusted admissions. Noted strong operational growth across payer categories except self-pay down 6%.

Medicare Advantage volume growth: +4.8% YoYTraditional Medicare case mix index: up modestlyMedicare Advantage case mix: flat to prior yearOverall Medicare combined adjusted admissions: +3.4% YoY

Answers to last quarter's watch list

Resiliency program quantification on Q4 — Management walked back the prior commitment. Rather than detailing the resiliency program this quarter or pre-committing to detailed Q4 disclosure, management said it will "limit our early thoughts for 2026 to our views on demand and the cost environment" with 2026 guidance now formally scheduled for the Q4 call. The resiliency program was referenced once in passing ("our resiliency plan should provide some relief") without scale.

Continue monitoring

Exchange equivalent admissions growth trajectory — Management declined to break out exchange volumes specifically this quarter, citing fluid policy. With self-pay down 6% and commercial up 3.7%, the implication is exchange volumes are still contributing to commercial but at a decelerating pace; without a hard number, the Q2 deceleration trend remains unrefuted.

Continue monitoring

Supplemental payments cash receipts in Q3 — Resolved with hard numbers: $240M Q3 net benefit, with the FY2025 net benefit guided to $250–350M vs FY24 (vs prior flat-to-+$100M). Tennessee was the largest driver with cash received; Kansas added nine months of catch-up; Texas added one month. Material upside to prior expectations, but management explicitly reframed the program as variable and timing-dependent.

Resolved positively

Medicaid volume trend — Not directly broken out in volume terms this quarter, but same-facility equivalent admissions re-accelerated to +2.4% from Q2's +1.7%, suggesting the Medicaid drag did not worsen and may have stabilized. The numeric guide was withdrawn, so the original "at risk on the low end" framing no longer applies.

Not resolved

Surgery case mix — Resolved positively: same-facility inpatient surgeries +1.4% (vs Q2 -0.3%) and outpatient surgeries +1.1% (vs Q2 -0.6%). Both reversed from Q2's declines, removing risk to the +6.6% revenue/admission tailwind.

Resolved positively

Professional fee inflation — Same-facility professional fees up 11% YoY in Q3, running hotter than baseline inflation, driven primarily by anesthesia and radiology. Management referenced "some pressures in certain areas" without committing to a breakeven timeline.

Continue monitoring

What to watch into next quarter

2026 guidance scope on the Q4 call — Management has now twice deferred forward disclosure (resiliency program scale and 2026 numbers). Whether Q4 delivers a hard FY2026 revenue/EBITDA/EPS range, or further qualitative deferral on EPTC outcomes, will define investor confidence in the forward setup.

Run-rate supplemental payments in Q4 and FY2026 — $250M expected in Q4 alone after $240M caught up in Q3 (including nine months of Kansas). The clean run-rate excluding catch-ups will set the 2026 baseline; watch for management to disclose a normalized number distinct from the FY25 vs FY24 net benefit framing.

Pending grandfathered DTP approvals (FL, GA, VA) — Guidance explicitly excludes any benefit from pending applications. Once the government reopens and CMS resumes approvals, any green-lights from Florida, Georgia, or Virginia would represent pure upside to the current guide and reset the 2026 baseline higher.

EPTC extension legislative outcome — Hazen acknowledged "greater recognition by legislators" but no resolution. Resolution (extension, partial extension, expiration) before the Q4 call will dictate whether 2026 exchange volumes can be modeled.

Equivalent admissions in Q4 vs the withdrawn 2–3% range — With the formal guide gone and respiratory season starting slow (50–70bps drag), watch whether Q4 prints below 2% — which would confirm the guide withdrawal was a hidden cut.

EBITDA margin trajectory — Q3 margin of 20.2% was up 150bps YoY, helped by the $240M supplemental tailwind. Strip the supplemental and the underlying margin trend looks softer; watch whether Q4 margin holds above the 20% level when supplemental run-rate normalizes.

DTP $2.3–2.4B baseline normalization — Justin Lake's question posited a $2.3–2.4B number; management did not confirm. Pending state approvals could push this materially higher; conversely, federal scrutiny of directed payment programs remains a structural risk.

Sources

HCA Healthcare Q3 2025 press release, filed October 24, 2025: https://www.sec.gov/Archives/edgar/data/860730/000119312525249345/hca-ex99_1.htm
Q3 2025 earnings call commentary from Sam Hazen (CEO) and Mike Marks (CFO), including Q&A with Anne Hines (Missoula Securities), AJ Rice (UBS), Justin Lake (Wolfe Research), Peter Chickering (Deutsche Bank), Ben Hendrix (RBC), and Scott Seidel (Goldman Sachs).
Tapebrief Q2 2025 HCA brief (prior watch list and guidance baseline).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.